Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dimebon alone · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Period 1 | EXPERIMENTAL | - |
| Period 2 | EXPERIMENTAL | - |
| Period 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Dimebon alone | DRUG | Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening |
| Dimebon + Ketoconazole | DRUG | Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening |
| Dimebon + Omeprazole | DRUG | Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening |
Inclusion Criteria: * Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. * Subjects must have either a CYP2D6 EM (n=12) or PM (n=12) status based on genotyping at screening. * Subjects must have a CYP2C19 EM status based ...
Top 20 of 24 competitors
Dimebon is an investigational small molecule being studied for Alzheimer's Disease. It is also being evaluated in the context of Huntington's Disease in clinical trials. As of the available data, it is in Phase 1 clinical development and is not approved by the FDA.
Dimebon is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange. The company is conducting clinical research to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
Dimebon is in Phase 1 clinical development. The available data shows one completed Phase 1 trial with 24 participants. It is an investigational drug and has not received FDA approval.
Dimebon has one completed clinical trial, NCT00931073, which was a Phase 1 study to estimate the effect of ketoconazole and omeprazole on the pharmacokinetics of Dimebon in healthy subjects who are normal or poor CYP2D6 metabolizers. The trial enrolled 24 participants in the United States.
Dimebon is also known by the name Dimebon alone. No other alternative names are provided in the available data. It is a small molecule being investigated for neurological conditions.